Becton, Dickinson and Company $BDX Stock Sold by Bfsg LLC

Bfsg LLC lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,567 shares of the medical instruments supplier’s stock after selling 14,569 shares during the quarter. Bfsg LLC’s holdings in Becton, Dickinson and Company were worth $2,965,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 30.1% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,117 shares of the medical instruments supplier’s stock worth $620,000 after purchasing an additional 722 shares during the last quarter. Jmac Enterprises LLC lifted its stake in Becton, Dickinson and Company by 28.6% in the third quarter. Jmac Enterprises LLC now owns 3,600 shares of the medical instruments supplier’s stock valued at $644,000 after buying an additional 800 shares during the last quarter. Verity Asset Management Inc. bought a new stake in Becton, Dickinson and Company in the third quarter valued at $206,000. Ascent Group LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at $291,000. Finally, 3Chopt Investment Partners LLC bought a new position in shares of Becton, Dickinson and Company during the third quarter worth about $221,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 6,907 shares of company stock worth $1,269,128. Corporate insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Zacks Research upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Bank of America boosted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Wolfe Research initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average target price of $185.07.

Becton, Dickinson and Company Trading Up 5.3%

Shares of NYSE:BDX opened at $208.57 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a market capitalization of $57.47 billion, a price-to-earnings ratio of 62.82, a PEG ratio of 13.36 and a beta of 0.22. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $209.84. The company has a 50 day moving average price of $187.23 and a 200 day moving average price of $170.20.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business posted $3.68 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.